UroGen Pharma's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 78.85.
UroGen Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 409.71.
UroGen Pharma's Days Payable for the
three
months ended in Mar. 2026 was 321.72.
Therefore, UroGen Pharma's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 166.84.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
UroGen Pharma Cash Conversion Cycle Related Terms
UroGen Pharma Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs SEPN, FTRE, MLTX: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, UroGen Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
UroGen Pharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a Cash Conversion Cycle of 166.84 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's Cash Conversion Cycle too high?
UroGen Pharma's current Cash Conversion Cycle is 166.84. The Biotechnology industry median Cash Conversion Cycle is 103.21. UroGen Pharma's value of 166.84 is 61.7% above this industry median. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Cash Conversion Cycle compare to SEPN and FTRE?
UroGen Pharma's Cash Conversion Cycle of 166.84 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.21. UroGen Pharma's value of 166.84 is 61.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.21, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Cash Conversion Cycle of 166.84 is 61.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Cash Conversion Cycle is 166.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.99, compared to a current price of €34.50 — trading 103.1% above its estimated fair value. The current Cash Conversion Cycle is 166.84 and 61.7% above the Biotechnology industry median of 103.21. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Cash Conversion Cycle is 166.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €34.50 is trading 103.1% above its estimated GF Value™ of €16.99.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Cash Conversion Cycle: 166.84
GF Value™: €16.99 vs. price of €34.50 (103.1% above fair value)
Industry Position: 61.7% above the Biotechnology median
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score
Get the complete analysis for FRA:UR8
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
